RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.